Top Growth Trends in the End Stage Renal Disease (ESRD) Drug Market: Insights into Market Size and Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of theEnd Stage Renal Disease (ESRD) Drug Market?
The increasing prevalence of obesity and diabetes is anticipated to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity, defined as an unusually high and unhealthy accumulation of fat, and diabetes, a long-term condition where the pancreas doesn’t produce sufficient insulin or the body is unable to use it effectively, are both health risks. Individuals with renal diseases can enhance their overall health by managing fluid and electrolyte levels, blood pressure, and eliminating waste products through dialysis. This could potentially lead to weight loss and better control of blood sugar levels. For example, World Obesity, a US-based organization focused on the study and management of obesity, predicted in March 2022 that the global obesity count could surge to 892 million in 2025, then further to 1,025 million in 2030. Similarly, the UK’s National Health Service projected in February 2023 that by 2030, the number of people with diabetes in the UK could escalate to 5.5 million, affecting almost 9% of the population. Hence, the growing instances of obesity and diabetes are expected to push the demand for ESRD drugs.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
#How Does the ProjectedEnd Stage Renal Disease (ESRD) Drug Market Growth Compare Over the Forecast Period?
The market size for drugs used in the treatment of end stage renal disease (ESRD) has experienced a swift expansion in recent years. There is projected growth from $131.41 billion in 2024 to $149.88 billion in 2025, showing a compound annual growth rate (CAGR) of 14.1%. Factors contributing to the growth during the historic period include rising cases of end stage renal disease, growth in the elderly population, better access to healthcare facilities, beneficial government strategies and policies, along with an increased uptake of renal replacement therapies.
In the coming years, the market size for drugs treating end stage renal disease (ESRD) is projected to expand rapidly, reaching $268.44 billion by 2029, propelled by a compound annual growth rate (CAGR) of 15.7%. This predicted growth in the forecast period stems from factors such as emerging drug therapies and innovative medicines, an escalation in healthcare spending, the rising global prevalence of chronic kidney diseases, personalized treatment strategies, supportive regulatory environments, and swift approvals of new treatments. The forecast period will also witness major trends including greater incidence of end stage renal disease, progress in treatment modalities, increased focus on precision medicine, the rise of combination therapies, and technological integration within the healthcare sector.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437
Which Upcoming Market Trends and Innovations Are Set to Influence theEnd Stage Renal Disease (ESRD) Drug Market’s Path Forward?
The rise in product innovations is a primary factor driving the popularity in the end-stage renal disease (ESRD) drug market. To remain competitive, leading companies in the ESRD drug market are focusing on the creation of innovative solutions. For example, in April 2022, UK-based pharmaceutical and biotechnology company GlaxoSmithKline PLC announced that their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has been approved by the US Food and Drug Administration (FDA) for potential treatment of patients with chronic kidney disease anemia (CKD). This breakthrough product is founded on the unique, Nobel-prize awarded scientific discovery that demonstrates how cells detect and adapt to the availability of oxygen.
Who Are the Dominant Market Players Pushing the Boundaries of theEnd Stage Renal Disease (ESRD) Drug Market?
Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
Order Your Report Now For A Swift Delivery:
What Are the Core Segments of the End Stage Renal Disease (ESRD) Drug Market, and How Do They Contribute to Growth?
The end stage renal disease (ESRD) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=9437&type=smpGlobal End Stage Renal Disease (ESRD) Drug Market, Global End Stage Renal Disease (ESRD) Drug Market Report, Global End Stage Renal Disease (ESRD) Drug Market Trends, Global End Stage Renal Disease (ESRD) Drug Market Size
Browse Through More Reports Similar to the Gobal End Stage Renal Disease (ESRD) Drug Maret 2025, By The Business Research Company:
Musculoskeletal Disorders Drugs Global Market Report 2022
Central Nervous System Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report
Cardiovascular Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
